Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 17 de 17
Filtrar
1.
Mol Cell ; 51(6): 829-39, 2013 Sep 26.
Artigo em Inglês | MEDLINE | ID: mdl-24035500

RESUMO

A chemicogenetic screen was performed in budding yeast mutants that have a weakened replication stress response. This identified an inhibitor of target of rapamycin (TOR) complexes 1 and 2 that selectively enhances the sensitivity of sgs1Δ cells to hydroxyurea and camptothecin. More importantly, the inhibitor has strong synthetic lethality in combination with either the break-inducing antibiotic Zeocin or ionizing radiation, independent of the strain background. Lethality correlates with a rapid fragmentation of chromosomes that occurs only when TORC2, but not TORC1, is repressed. Genetic inhibition of Tor2 kinase, or its downstream effector kinases Ypk1/Ypk2, conferred similar synergistic effects in the presence of Zeocin. Given that Ypk1/Ypk2 controls the actin cytoskeleton, we tested the effects of actin modulators latrunculin A and jasplakinolide. These phenocopy TORC2 inhibition on Zeocin, although modulation of calcineurin-sensitive transcription does not. These results implicate TORC2-mediated actin filament regulation in the survival of low levels of DNA damage.


Assuntos
Instabilidade Genômica , Complexos Multiproteicos/genética , Proteínas de Saccharomyces cerevisiae/genética , Saccharomyces cerevisiae/genética , Serina-Treonina Quinases TOR/genética , Fatores de Transcrição/genética , Actinas/antagonistas & inibidores , Actinas/metabolismo , Bleomicina/farmacologia , Compostos Bicíclicos Heterocíclicos com Pontes/farmacologia , Cromossomos/efeitos dos fármacos , Cromossomos/genética , Cromossomos/efeitos da radiação , Dano ao DNA/genética , Replicação do DNA/efeitos dos fármacos , Replicação do DNA/efeitos da radiação , Instabilidade Genômica/efeitos dos fármacos , Instabilidade Genômica/efeitos da radiação , Quinase 3 da Glicogênio Sintase/metabolismo , Alvo Mecanístico do Complexo 2 de Rapamicina , Complexos Multiproteicos/antagonistas & inibidores , Complexos Multiproteicos/metabolismo , Radiação Ionizante , Proteínas de Saccharomyces cerevisiae/antagonistas & inibidores , Proteínas de Saccharomyces cerevisiae/metabolismo , Transdução de Sinais/efeitos dos fármacos , Transdução de Sinais/efeitos da radiação , Serina-Treonina Quinases TOR/antagonistas & inibidores , Serina-Treonina Quinases TOR/metabolismo , Tiazolidinas/farmacologia , Fatores de Transcrição/antagonistas & inibidores , Fatores de Transcrição/metabolismo
2.
J Nat Prod ; 83(4): 965-971, 2020 04 24.
Artigo em Inglês | MEDLINE | ID: mdl-32182062

RESUMO

Kendomycin is a small-molecule natural product that has gained significant attention due to reported cytotoxicity against pathogenic bacteria and fungi as well as a number of cancer cell lines. Despite significant biomedical interest and attempts to reveal its mechanism of action, the cellular target of kendomycin remains disputed. Herein it is shown that kendomycin induces cellular responses indicative of cation stress comparable to the effects of established iron chelators. Furthermore, addition of excess iron and copper attenuated kendomycin cytotoxicity in bacteria, yeast, and mammalian cells. Finally, NMR analysis demonstrated a direct interaction with cations, corroborating a close link between the observed kendomycin polypharmacology across different species and modulation of iron and/or copper levels.


Assuntos
Antibacterianos/farmacologia , Antibióticos Antineoplásicos/farmacologia , Antifúngicos/farmacologia , Bactérias/efeitos dos fármacos , Quelantes/farmacologia , Fungos/efeitos dos fármacos , Rifabutina/análogos & derivados , Cátions , Linhagem Celular , Cobre/metabolismo , Ferro/metabolismo , Leupeptinas/farmacologia , Testes de Sensibilidade Microbiana , Mutagênese , Rifabutina/farmacologia , Leveduras/efeitos dos fármacos
3.
J Biol Chem ; 293(31): 12043-12053, 2018 08 03.
Artigo em Inglês | MEDLINE | ID: mdl-29895620

RESUMO

Target of rapamycin complex 2 (TORC2) is a widely conserved serine/threonine protein kinase. In the yeast Saccharomyces cerevisiae, TORC2 is essential, playing a key role in plasma membrane homeostasis. In this role, TORC2 regulates diverse processes, including sphingolipid synthesis, glycerol production and efflux, polarization of the actin cytoskeleton, and endocytosis. The major direct substrate of TORC2 is the AGC-family kinase Ypk1. Ypk1 connects TORC2 signaling to actin polarization and to endocytosis via the flippase kinases Fpk1 and Fpk2. Here, we report that Fpk1 mediates TORC2 signaling to control actin polarization, but not endocytosis, via aminophospholipid flippases. To search for specific targets of these flippase kinases, we exploited the fact that Fpk1 prefers to phosphorylate Ser residues within the sequence RXS(L/Y)(D/E), which is present ∼90 times in the yeast proteome. We observed that 25 of these sequences are phosphorylated by Fpk1 in vitro We focused on one sequence hit, the Ark/Prk-family kinase Akl1, as this kinase previously has been implicated in endocytosis. Using a potent ATP-competitive small molecule, CMB4563, to preferentially inhibit TORC2, we found that Fpk1-mediated Akl1 phosphorylation inhibits Akl1 activity, which, in turn, reduces phosphorylation of Pan1 and of other endocytic coat proteins and ultimately contributes to a slowing of endocytosis kinetics. These results indicate that the regulation of actin polarization and endocytosis downstream of TORC2 is signaled through separate pathways that bifurcate at the level of the flippase kinases.


Assuntos
Endocitose/genética , Regulação Fúngica da Expressão Gênica , Alvo Mecanístico do Complexo 2 de Rapamicina/genética , Proteínas dos Microfilamentos/metabolismo , Proteínas de Saccharomyces cerevisiae/metabolismo , Saccharomyces cerevisiae/metabolismo , Citoesqueleto de Actina/efeitos dos fármacos , Citoesqueleto de Actina/metabolismo , Citoesqueleto de Actina/ultraestrutura , Membrana Celular/efeitos dos fármacos , Membrana Celular/metabolismo , Membrana Celular/ultraestrutura , Endocitose/efeitos dos fármacos , Glicerol/metabolismo , Quinase 3 da Glicogênio Sintase/genética , Quinase 3 da Glicogênio Sintase/metabolismo , Alvo Mecanístico do Complexo 2 de Rapamicina/antagonistas & inibidores , Alvo Mecanístico do Complexo 2 de Rapamicina/metabolismo , Proteínas dos Microfilamentos/genética , Fosforilação/efeitos dos fármacos , Inibidores de Proteínas Quinases/farmacologia , Proteínas Quinases/genética , Proteínas Quinases/metabolismo , Saccharomyces cerevisiae/efeitos dos fármacos , Saccharomyces cerevisiae/genética , Saccharomyces cerevisiae/ultraestrutura , Proteínas de Saccharomyces cerevisiae/genética , Serina/metabolismo , Transdução de Sinais , Esfingolipídeos/biossíntese
4.
Nat Chem Biol ; 13(12): 1239-1244, 2017 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-28991239

RESUMO

Tim17 and Tim23 are the main subunits of the TIM23 complex, one of the two major essential mitochondrial inner-membrane protein translocon machineries (TIMs). No chemical probes that specifically inhibit TIM23-dependent protein import were known to exist. Here we show that the natural product stendomycin, produced by Streptomyces hygroscopicus, is a potent and specific inhibitor of the TIM23 complex in yeast and mammalian cells. Furthermore, stendomycin-mediated blockage of the TIM23 complex does not alter normal processing of the major regulatory mitophagy kinase PINK1, but TIM23 is required to stabilize PINK1 on the outside of mitochondria to initiate mitophagy upon membrane depolarization.


Assuntos
Proteínas Mitocondriais/metabolismo , Peptídeos/farmacologia , Proteínas de Saccharomyces cerevisiae/antagonistas & inibidores , Peptídeos Catiônicos Antimicrobianos , Relação Dose-Resposta a Droga , Células HeLa , Humanos , Proteínas de Membrana Transportadoras/metabolismo , Mitocôndrias/efeitos dos fármacos , Mitocôndrias/metabolismo , Proteínas do Complexo de Importação de Proteína Precursora Mitocondrial , Estrutura Molecular , Peptídeos/química , Transporte Proteico/efeitos dos fármacos , Saccharomyces cerevisiae/efeitos dos fármacos , Saccharomyces cerevisiae/metabolismo , Proteínas de Saccharomyces cerevisiae/metabolismo , Relação Estrutura-Atividade , Células Tumorais Cultivadas
5.
PLoS Genet ; 12(11): e1006374, 2016 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-27855158

RESUMO

Invasive infections by fungal pathogens cause more deaths than malaria worldwide. We found the ergoline compound NGx04 in an antifungal screen, with selectivity over mammalian cells. High-resolution chemogenomics identified the lipid transfer protein Sec14p as the target of NGx04 and compound-resistant mutations in Sec14p define compound-target interactions in the substrate binding pocket of the protein. Beyond its essential lipid transfer function in a variety of pathogenic fungi, Sec14p is also involved in secretion of virulence determinants essential for the pathogenicity of fungi such as Cryptococcus neoformans, making Sec14p an attractive antifungal target. Consistent with this dual function, we demonstrate that NGx04 inhibits the growth of two clinical isolates of C. neoformans and that NGx04-related compounds have equal and even higher potency against C. neoformans. Furthermore NGx04 analogues showed fungicidal activity against a fluconazole resistant C. neoformans strain. In summary, we present genetic evidence that NGx04 inhibits fungal Sec14p and initial data supporting NGx04 as a novel antifungal starting point.


Assuntos
Proteínas de Transporte/química , Criptococose/tratamento farmacológico , Cryptococcus neoformans/efeitos dos fármacos , Ergolinas/farmacologia , Metabolismo dos Lipídeos/efeitos dos fármacos , Antifúngicos/farmacologia , Proteínas de Transporte/genética , Criptococose/microbiologia , Cryptococcus neoformans/genética , Cryptococcus neoformans/patogenicidade , Ergolinas/química , Humanos , Testes de Sensibilidade Microbiana , Conformação Proteica , Saccharomyces cerevisiae/química , Saccharomyces cerevisiae/genética
6.
J Biol Chem ; 290(24): 14963-78, 2015 Jun 12.
Artigo em Inglês | MEDLINE | ID: mdl-25882841

RESUMO

Target of rapamycin is a Ser/Thr kinase that operates in two conserved multiprotein complexes, TORC1 and TORC2. Unlike TORC1, TORC2 is insensitive to rapamycin, and its functional characterization is less advanced. Previous genetic studies demonstrated that TORC2 depletion leads to loss of actin polarization and loss of endocytosis. To determine how TORC2 regulates these readouts, we engineered a yeast strain in which TORC2 can be specifically and acutely inhibited by the imidazoquinoline NVP-BHS345. Kinetic analyses following inhibition of TORC2, supported with quantitative phosphoproteomics, revealed that TORC2 regulates these readouts via distinct pathways as follows: rapidly through direct protein phosphorylation cascades and slowly through indirect changes in the tensile properties of the plasma membrane. The rapid signaling events are mediated in large part through the phospholipid flippase kinases Fpk1 and Fpk2, whereas the slow signaling pathway involves increased plasma membrane tension resulting from a gradual depletion of sphingolipids. Additional hits in our phosphoproteomic screens highlight the intricate control TORC2 exerts over diverse aspects of eukaryote cell physiology.


Assuntos
Actinas/metabolismo , Endocitose , Complexos Multiproteicos/fisiologia , Saccharomyces cerevisiae/metabolismo , Serina-Treonina Quinases TOR/fisiologia , Proteínas Fúngicas/metabolismo , Alvo Mecanístico do Complexo 2 de Rapamicina , Fosforilação , Análise de Componente Principal , Proteínas Quinases/metabolismo , Proteômica , Proteínas de Saccharomyces cerevisiae/metabolismo , Transdução de Sinais
7.
Cell Mol Gastroenterol Hepatol ; 17(6): 1007-1024, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-38336172

RESUMO

BACKGROUND & AIMS: In the classic form of α1-antitrypsin deficiency (ATD), the misfolded α1-antitrypsin Z (ATZ) variant accumulates in the endoplasmic reticulum (ER) of liver cells. A gain-of-function proteotoxic mechanism is responsible for chronic liver disease in a subgroup of homozygotes. Proteostatic response pathways, including conventional endoplasmic reticulum-associated degradation and autophagy, have been proposed as the mechanisms that allow cellular adaptation and presumably protection from the liver disease phenotype. Recent studies have concluded that a distinct lysosomal pathway called endoplasmic reticulum-to-lysosome completely supplants the role of the conventional macroautophagy pathway in degradation of ATZ. Here, we used several state-of-the-art approaches to characterize the proteostatic responses more fully in cellular systems that model ATD. METHODS: We used clustered regularly interspaced short palindromic repeats (CRISPR)-mediated genome editing coupled to a cell selection step by fluorescence-activated cell sorter to perform screening for proteostasis genes that regulate ATZ accumulation and combined that with selective genome editing in 2 other model systems. RESULTS: Endoplasmic reticulum-associated degradation genes are key early regulators and multiple autophagy genes, from classic as well as from ER-to-lysosome and other newly described ER-phagy pathways, participate in degradation of ATZ in a manner that is temporally regulated and evolves as ATZ accumulation persists. Time-dependent changes in gene expression are accompanied by specific ultrastructural changes including dilation of the ER, formation of globular inclusions, budding of autophagic vesicles, and alterations in the overall shape and component parts of mitochondria. CONCLUSIONS: Macroautophagy is a critical component of the proteostasis response to cellular ATZ accumulation and it becomes more important over time as ATZ synthesis continues unabated. Multiple subtypes of macroautophagy and nonautophagic lysosomal degradative pathways are needed to respond to the high concentrations of misfolded protein that characterizes ATD and these pathways are attractive candidates for genetic variants that predispose to the hepatic phenotype.


Assuntos
Degradação Associada com o Retículo Endoplasmático , Retículo Endoplasmático , Lisossomos , Macroautofagia , Proteostase , Deficiência de alfa 1-Antitripsina , alfa 1-Antitripsina , Deficiência de alfa 1-Antitripsina/patologia , Deficiência de alfa 1-Antitripsina/genética , Deficiência de alfa 1-Antitripsina/metabolismo , Humanos , Lisossomos/metabolismo , alfa 1-Antitripsina/metabolismo , alfa 1-Antitripsina/genética , Retículo Endoplasmático/metabolismo , Sistemas CRISPR-Cas , Autofagia/genética , Edição de Genes
8.
Cell Chem Biol ; 25(3): 279-290.e7, 2018 03 15.
Artigo em Inglês | MEDLINE | ID: mdl-29307839

RESUMO

Invasive fungal infections are accompanied by high mortality rates that range up to 90%. At present, only three different compound classes are available for use in the clinic, and these often suffer from low bioavailability, toxicity, and drug resistance. These issues emphasize an urgent need for novel antifungal agents. Herein, we report the identification of chemically versatile benzamide and picolinamide scaffolds with antifungal properties. Chemogenomic profiling and biochemical assays with purified protein identified Sec14p, the major phosphatidylinositol/phosphatidylcholine transfer protein in Saccharomyces cerevisiae, as the sole essential target for these compounds. A functional variomics screen identified resistance-conferring residues that localized to the lipid-binding pocket of Sec14p. Determination of the X-ray co-crystal structure of a Sec14p-compound complex confirmed binding in this cavity and rationalized both the resistance-conferring residues and the observed structure-activity relationships. Taken together, these findings open new avenues for rational compound optimization and development of novel antifungal agents.


Assuntos
Antifúngicos/metabolismo , Benzamidas/química , Ácidos Picolínicos/química , Amidas/química , Amidas/metabolismo , Amidas/farmacologia , Sequência de Aminoácidos , Antifúngicos/química , Antifúngicos/farmacologia , Aspergillus/efeitos dos fármacos , Benzamidas/metabolismo , Benzamidas/farmacologia , Sítios de Ligação , Candida albicans/efeitos dos fármacos , Cristalografia por Raios X , Farmacorresistência Fúngica/efeitos dos fármacos , Testes de Sensibilidade Microbiana , Simulação de Dinâmica Molecular , Mutagênese Sítio-Dirigida , Proteínas de Transferência de Fosfolipídeos/química , Proteínas de Transferência de Fosfolipídeos/genética , Proteínas de Transferência de Fosfolipídeos/metabolismo , Ácidos Picolínicos/metabolismo , Ácidos Picolínicos/farmacologia , Estrutura Terciária de Proteína , Saccharomyces cerevisiae/efeitos dos fármacos , Saccharomyces cerevisiae/metabolismo , Proteínas de Saccharomyces cerevisiae/química , Proteínas de Saccharomyces cerevisiae/genética , Proteínas de Saccharomyces cerevisiae/metabolismo , Alinhamento de Sequência , Relação Estrutura-Atividade
9.
ACS Chem Biol ; 12(9): 2264-2269, 2017 09 15.
Artigo em Inglês | MEDLINE | ID: mdl-28796488

RESUMO

The microbial metabolite Chivosazole F has been described to affect the cytoskeleton and to inhibit actin polymerization in vitro. Applying orthogonal genomic and proteomics approaches, we now show for the first time that Chivosazole F exerts its effect by directly interacting with actin and demonstrate the cellular impact of Chivosazole F in an unbiased, genome-wide context in yeast and in mammalian cells. Furthermore, mutation-based resistance mapping identifies two SNPs located in the putative Chivosazole F binding site of actin. Comparing chemogenomic profiles and responses to the Chivosazole F-resistant SNPs shows a partially conserved mechanism of action for Chivosazole F and Latrunculin A, but clear divergence from Chondramide. In addition, C14orf80 is an evolutionarily highly conserved ORF, lacking any functional annotation. As editing of C14orf80 leads to Chivosazole F hyper-resistance, we propose a function for this gene product in counteracting perturbation of actin filaments.


Assuntos
Actinas/metabolismo , Compostos Bicíclicos Heterocíclicos com Pontes/farmacologia , Depsipeptídeos/farmacologia , Macrolídeos/farmacologia , Tiazolidinas/farmacologia , Citoesqueleto de Actina/efeitos dos fármacos , Citoesqueleto de Actina/genética , Citoesqueleto de Actina/metabolismo , Actinas/genética , Sítios de Ligação , Compostos Bicíclicos Heterocíclicos com Pontes/química , Depsipeptídeos/química , Células HEK293 , Humanos , Macrolídeos/química , Mutação , Myxococcales/química , Tiazolidinas/química
10.
Cell Rep ; 19(3): 451-460, 2017 04 18.
Artigo em Inglês | MEDLINE | ID: mdl-28423309

RESUMO

Flavivirus infections by Zika and dengue virus impose a significant global healthcare threat with no US Food and Drug Administration (FDA)-approved vaccination or specific antiviral treatment available. Here, we present the discovery of an anti-flaviviral natural product named cavinafungin. Cavinafungin is a potent and selectively active compound against Zika and all four dengue virus serotypes. Unbiased, genome-wide genomic profiling in human cells using a novel CRISPR/Cas9 protocol identified the endoplasmic-reticulum-localized signal peptidase as the efficacy target of cavinafungin. Orthogonal profiling in S. cerevisiae followed by the selection of resistant mutants pinpointed the catalytic subunit of the signal peptidase SEC11 as the evolutionary conserved target. Biochemical analysis confirmed a rapid block of signal sequence cleavage of both host and viral proteins by cavinafungin. This study provides an effective compound against the eukaryotic signal peptidase and independent confirmation of the recently identified critical role of the signal peptidase in the replicative cycle of flaviviruses.


Assuntos
Produtos Biológicos/farmacologia , Vírus da Dengue/fisiologia , Lipopeptídeos/farmacologia , Replicação Viral/efeitos dos fármacos , Zika virus/fisiologia , Produtos Biológicos/química , Sistemas CRISPR-Cas/genética , Vírus da Dengue/efeitos dos fármacos , Técnicas de Silenciamento de Genes , Genoma Humano , Genômica , Células HCT116 , Humanos , Lipopeptídeos/química , Proteínas de Membrana , Subunidades Proteicas/metabolismo , Saccharomyces cerevisiae/efeitos dos fármacos , Saccharomyces cerevisiae/genética , Serina Endopeptidases , Proteínas Virais/metabolismo , Zika virus/efeitos dos fármacos
11.
J Biomol Screen ; 21(3): 306-15, 2016 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-26459507

RESUMO

Phenotypic screens are effective starting points to identify compounds with desirable activities. To find novel antifungals, we conducted a phenotypic screen in Saccharomyces cerevisiae and identified two discrete scaffolds with good growth inhibitory characteristics. Lack of broad-spectrum activity against pathogenic fungi called for directed chemical compound optimization requiring knowledge of the molecular target. Chemogenomic profiling identified effects on geranylgeranyltransferase I (GGTase I), an essential enzyme that prenylates proteins involved in cell signaling, such as Cdc42p and Rho1p. Selection of resistant mutants against both compounds confirmed the target hypothesis and enabled mapping of the compound binding site to the substrate binding pocket. Differential resistance-conferring mutations and selective substrate competition demonstrate distinct binding modes for the two chemotypes. Exchange of the S. cerevisiae GGTase I subunits with those of Candida albicans resulted in an absence of growth inhibition for both compounds, thus confirming the identified target as well as the narrow antifungal spectrum of activity. This prenylation pathway is reported to be nonessential in pathogenic species and challenges the therapeutic value of these leads while demonstrating the importance of an integrated target identification platform following a phenotypic screen.


Assuntos
Alquil e Aril Transferases/antagonistas & inibidores , Antifúngicos/farmacologia , Descoberta de Drogas/métodos , Inibidores Enzimáticos/farmacologia , Testes de Sensibilidade Microbiana , Alquil e Aril Transferases/química , Alquil e Aril Transferases/genética , Alquil e Aril Transferases/metabolismo , Antifúngicos/química , Farmacorresistência Fúngica , Inibidores Enzimáticos/química , Perfilação da Expressão Gênica , Metabolômica/métodos , Modelos Moleculares , Conformação Molecular , Mutação , Ligação Proteica , Saccharomyces cerevisiae/efeitos dos fármacos , Saccharomyces cerevisiae/enzimologia , Saccharomyces cerevisiae/genética
12.
Nat Commun ; 6: 8613, 2015 Oct 12.
Artigo em Inglês | MEDLINE | ID: mdl-26456460

RESUMO

FR171456 is a natural product with cholesterol-lowering properties in animal models, but its molecular target is unknown, which hinders further drug development. Here we show that FR171456 specifically targets the sterol-4-alpha-carboxylate-3-dehydrogenase (Saccharomyces cerevisiae--Erg26p, Homo sapiens--NSDHL (NAD(P) dependent steroid dehydrogenase-like)), an essential enzyme in the ergosterol/cholesterol biosynthesis pathway. FR171456 significantly alters the levels of cholesterol pathway intermediates in human and yeast cells. Genome-wide yeast haploinsufficiency profiling experiments highlight the erg26/ERG26 strain, and multiple mutations in ERG26 confer resistance to FR171456 in growth and enzyme assays. Some of these ERG26 mutations likely alter Erg26 binding to FR171456, based on a model of Erg26. Finally, we show that FR171456 inhibits an artificial Hepatitis C viral replicon, and has broad antifungal activity, suggesting potential additional utility as an anti-infective. The discovery of the target and binding site of FR171456 within the target will aid further development of this compound.


Assuntos
3-Hidroxiesteroide Desidrogenases/antagonistas & inibidores , Antifúngicos/química , Colesterol/análogos & derivados , Proteínas de Saccharomyces cerevisiae/antagonistas & inibidores , Saccharomyces cerevisiae/genética , 3-Hidroxiesteroide Desidrogenases/genética , Candida albicans , Colesterol/química , Farmacorresistência Fúngica/genética , Ergosterol/biossíntese , Mutação , Proteínas de Saccharomyces cerevisiae/genética
13.
J Biomol Screen ; 9(6): 498-505, 2004 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-15452336

RESUMO

SpeedScreen is a novel, label-free, in-solution, affinity-based selection methodology for high-throughput screening (HTS) developed at Novartis Pharma. The SpeedScreen protocol comprises in-solution affinity selection, followed by size exclusion chromatography in combination with microbore-liquid-chromatography/electrospray-ionization mass spectrometry (micro-LC/ESI-MS). The authors describe the basic concept behind assay development, HTS, and data analysis with the SpeedScreen technology. Advantages and limitations of SpeedScreen compared to alternative screening technologies are discussed, and an example is given from a SpeedScreen campaign applying this innovative affinity selection concept in HTS.


Assuntos
Desenho de Fármacos , Genômica , Chumbo/análise , Cromatografia em Gel/métodos , Cromatografia Líquida de Alta Pressão/métodos , Desenho de Equipamento , Chumbo/química , Espectrometria de Massas/métodos , Modelos Teóricos , Ligação Proteica , Sensibilidade e Especificidade , Espectrometria de Massas por Ionização por Electrospray/métodos , Tecnologia Farmacêutica/instrumentação
14.
J Biomol Screen ; 9(7): 569-77, 2004 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-15475476

RESUMO

The beta isoform of the heat shock protein 90 (Hsp90beta) is a cellular chaperone required for the maturation of key proteins involved in growth response to extracellular factors as well as oncogenic transformation of various cell types. Compounds that inhibit the function of Hsp90beta are thus believed to have potential as novel anticancer drugs. To date, 2 fungal metabolites are known to inhibit Hsp90beta. However, insolubility and liver toxicity restrict the clinical use of these molecules. The limitation to identify novel and safe Hsp90beta inhibitors is that presently no suitable high-throughput screening assay is available. Here, the authors present the development of a homogenous assay based on 2-dimensional fluorescence intensity distribution analysis of tetramethyl-rhodamine (TAMRA)-labeled radicicol bound to Hsp90beta. Furthermore, the assay has been shown to be compatible with the confocal nanoscreening platform Mark II from Evotec-Technologies and can therefore be used for miniaturized high-throughput screening. The applied detection technology provides critical information about the nature of biomolecular interaction at the thermodynamic equilibrium, such as affinity constants and stoichiometric parameters of the binding. The assay is used to identify small molecular weight compounds displacing TAMRA-radicicol. Such compounds are believed to be important molecules in the discovery of novel anticancer drugs.


Assuntos
Bioensaio/métodos , Proteínas de Choque Térmico HSP90/antagonistas & inibidores , Fluorescência , Humanos , Cinética , Lactonas/química , Macrolídeos , Miniaturização , Estrutura Molecular , Nanotecnologia , Ligação Proteica , Ensaio Radioligante
15.
Microbiol Res ; 169(2-3): 107-20, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-24360837

RESUMO

Due to evolutionary conservation of biology, experimental knowledge captured from genetic studies in eukaryotic model organisms provides insight into human cellular pathways and ultimately physiology. Yeast chemogenomic profiling is a powerful approach for annotating cellular responses to small molecules. Using an optimized platform, we provide the relative sensitivities of the heterozygous and homozygous deletion collections for nearly 1800 biologically active compounds. The data quality enables unique insights into pathways that are sensitive and resistant to a given perturbation, as demonstrated with both known and novel compounds. We present examples of novel compounds that inhibit the therapeutically relevant fatty acid synthase and desaturase (Fas1p and Ole1p), and demonstrate how the individual profiles facilitate hypothesis-driven experiments to delineate compound mechanism of action. Importantly, the scale and diversity of tested compounds yields a dataset where the number of modulated pathways approaches saturation. This resource can be used to map novel biological connections, and also identify functions for unannotated genes. We validated hypotheses generated by global two-way hierarchical clustering of profiles for (i) novel compounds with a similar mechanism of action acting upon microtubules or vacuolar ATPases, and (ii) an un-annotated ORF, YIL060w, that plays a role in respiration in the mitochondria. Finally, we identify and characterize background mutations in the widely used yeast deletion collection which should improve the interpretation of past and future screens throughout the community. This comprehensive resource of cellular responses enables the expansion of our understanding of eukaryotic pathway biology.


Assuntos
Proteínas de Saccharomyces cerevisiae/genética , Saccharomyces cerevisiae/química , Saccharomyces cerevisiae/genética , Antifúngicos/farmacologia , Vias Biossintéticas , Farmacorresistência Fúngica , Regulação Fúngica da Expressão Gênica , Ensaios de Triagem em Larga Escala , Dados de Sequência Molecular , Filogenia , Saccharomyces cerevisiae/classificação , Saccharomyces cerevisiae/efeitos dos fármacos , Proteínas de Saccharomyces cerevisiae/metabolismo
16.
Anal Biochem ; 343(2): 244-55, 2005 Aug 15.
Artigo em Inglês | MEDLINE | ID: mdl-15963938

RESUMO

Deubiquitinating enzymes (DUBs) catalyze the removal of attached ubiquitin molecules from amino groups of target proteins. The large family of DUBs plays an important role in the regulation of the intracellular homeostasis of different proteins and influences therefore key events such as cell division, apoptosis, etc. The DUB family members UCH-L3 and USP2 are believed to inhibit the degradation of various tumor-growth-promoting proteins by removing the trigger for degradation. Inhibitors of these enzymes should therefore lead to enhanced degradation of oncoproteins and may thus stop tumor growth. To develop an enzymatic assay for the search of UCH-L3 and USP2 inhibitors, C-terminally labeled ubiquitin substrates were enzymatically synthesized. We have used the ubiquitin-activating enzyme E1 and one of the ubiquitin-conjugating enzymes E2 to attach a fluorescent lysine derivative to the C terminus of ubiquitin. Since only the epsilon-NH(2) group of the lysine derivatives was free and reactive, the conjugates closely mimic the isopeptide bond between the ubiquitin and the lysine side chains of the targeted proteins. Various substrates were synthesized by this approach and characterized enzymatically with the two DUBs. The variant consisting of the fusion protein between the large N-terminal NusA tag and the ubiquitin which was modified with alpha-NH(2)-tetramethylrhodamin-lysine, was found to give the highest dynamic range in a fluorescence polarization readout. Therefore we have chosen this substrate for the development of a miniaturized, fluorescence-polarization-based high-throughput screening assay.


Assuntos
Corantes Fluorescentes/síntese química , Ubiquitina/análogos & derivados , Ubiquitina/síntese química , Cromatografia Líquida de Alta Pressão , Eletroforese em Gel de Poliacrilamida , Endopeptidases/química , Endopeptidases/metabolismo , Corantes Fluorescentes/química , Cinética , Lisina/química , Lisina/metabolismo , Rodaminas/química , Rodaminas/metabolismo , Fatores de Tempo , Ubiquitina/química , Ubiquitina Tiolesterase/química , Ubiquitina Tiolesterase/metabolismo
17.
J Biol Chem ; 279(47): 49330-7, 2004 Nov 19.
Artigo em Inglês | MEDLINE | ID: mdl-15337744

RESUMO

The crystal structure of the ligand binding domain (LBD) of the estrogen-related receptor alpha (ERRalpha, NR3B1) complexed with a coactivator peptide from peroxisome proliferator-activated receptor coactivator-1alpha (PGC-1alpha) reveals a transcriptionally active conformation in the absence of a ligand. This is the first x-ray structure of ERRalpha LBD, solved to a resolution of 2.5 A, and the first structure of a PGC-1alpha complex. The putative ligand binding pocket (LBP) of ERRalpha is almost completely occupied by side chains, in particular with the bulky side chain of Phe328 (corresponding to Ala272 in ERRgamma and Ala350 in estrogen receptor alpha). Therefore, a ligand of a size equivalent to more than approximately 4 carbon atoms could only bind in the LBP, if ERRalpha would undergo a major conformational change (in particular the ligand would displace H12 from its agonist position). The x-ray structure thus provides strong evidence for ligand-independent transcriptional activation by ERRalpha. The interactions of PGC-1alpha with ERRalpha also reveal for the first time the atomic details of how a coactivator peptide containing an inverted LXXLL motif (namely a LLXYL motif) binds to a LBD. In addition, we show that a PGC-1alpha peptide containing this nuclear box motif from the L3 site binds ERRalpha LBD with a higher affinity than a peptide containing a steroid receptor coactivator-1 motif and that the affinity is further enhanced when all three leucine-rich regions of PGC-1alpha are present.


Assuntos
Proteínas de Choque Térmico/metabolismo , Receptores Citoplasmáticos e Nucleares/química , Receptores de Estrogênio/química , Fatores de Transcrição/metabolismo , Ativação Transcricional , Motivos de Aminoácidos , Animais , Sítios de Ligação , Carbono/química , Linhagem Celular , Núcleo Celular/metabolismo , Clonagem Molecular , Cristalografia por Raios X , Relação Dose-Resposta a Droga , Histona Acetiltransferases , Humanos , Insetos , Leucina/química , Ligantes , Modelos Moleculares , Mutação , Coativador 1 de Receptor Nuclear , Peptídeos/química , Coativador 1-alfa do Receptor gama Ativado por Proliferador de Peroxissomo , Ligação Proteica , Conformação Proteica , Estrutura Terciária de Proteína , Receptores Citoplasmáticos e Nucleares/metabolismo , Receptores de Estrogênio/metabolismo , Temperatura , Receptor ERRalfa Relacionado ao Estrogênio
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA